JP2008530582A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530582A5
JP2008530582A5 JP2007556362A JP2007556362A JP2008530582A5 JP 2008530582 A5 JP2008530582 A5 JP 2008530582A5 JP 2007556362 A JP2007556362 A JP 2007556362A JP 2007556362 A JP2007556362 A JP 2007556362A JP 2008530582 A5 JP2008530582 A5 JP 2008530582A5
Authority
JP
Japan
Prior art keywords
cancer
cyr61
level
antibody
urine sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007556362A
Other languages
English (en)
Japanese (ja)
Other versions
JP5006802B2 (ja
JP2008530582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005812 external-priority patent/WO2006089212A2/en
Publication of JP2008530582A publication Critical patent/JP2008530582A/ja
Publication of JP2008530582A5 publication Critical patent/JP2008530582A5/ja
Application granted granted Critical
Publication of JP5006802B2 publication Critical patent/JP5006802B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007556362A 2005-02-18 2006-02-17 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ Expired - Fee Related JP5006802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65411105P 2005-02-18 2005-02-18
US60/654,111 2005-02-18
PCT/US2006/005812 WO2006089212A2 (en) 2005-02-18 2006-02-17 Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

Publications (3)

Publication Number Publication Date
JP2008530582A JP2008530582A (ja) 2008-08-07
JP2008530582A5 true JP2008530582A5 (enExample) 2009-04-16
JP5006802B2 JP5006802B2 (ja) 2012-08-22

Family

ID=36917123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556362A Expired - Fee Related JP5006802B2 (ja) 2005-02-18 2006-02-17 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１

Country Status (7)

Country Link
US (4) US7858324B2 (enExample)
EP (1) EP1849002A4 (enExample)
JP (1) JP5006802B2 (enExample)
CN (1) CN101120252A (enExample)
AU (1) AU2006214105A1 (enExample)
CA (1) CA2598217A1 (enExample)
WO (1) WO2006089212A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CN101120252A (zh) * 2005-02-18 2008-02-06 儿童医疗中心有限公司 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
EP2126577B1 (en) * 2007-03-29 2013-03-13 Fujirebio Diagnostics, Inc. Use of he4 for assessment of breast cancers
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US11137401B2 (en) 2008-08-05 2021-10-05 Toray Industries, Inc. Method for detecting cancer using CAPRIN-1 as a marker
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
CN101747435B (zh) * 2008-12-18 2013-06-19 上海市免疫学研究所 一种中和cyr61的单克隆抗体(杂交瘤)及其应用
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US20140220018A1 (en) * 2011-06-16 2014-08-07 Giovanni M. Pitari Biomarkers for epithelial cancer diagnosis and treatment
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
TR201808595T4 (tr) 2011-08-04 2018-07-23 Toray Industries Kanser hastalıklarının tedavisi ve/veya profilaksisi için farmasötik bileşim.
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2611197C2 (ru) 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
IN2014KN01715A (enExample) 2012-02-21 2015-10-23 Toray Industries
CN104114583B (zh) 2012-02-21 2019-11-19 东丽株式会社 癌的治疗和/或预防用药物组合物
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
EP2832366B1 (en) 2012-03-30 2017-11-08 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
ES2769831T3 (es) 2012-07-19 2020-06-29 Toray Industries Método para detectar cáncer
JP6244911B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
HUE042081T2 (hu) 2013-08-09 2019-06-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
CN107422125A (zh) * 2016-05-23 2017-12-01 中国医学科学院肿瘤医院 与肌层浸润性膀胱癌相关的尿液蛋白质标志物
EP3364190A1 (en) 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN108752454B (zh) * 2018-06-19 2021-07-20 中山大学孙逸仙纪念医院 一种人CYR61蛋白Ser188位点磷酸化抗原、抗体及其制备方法和应用
CN111426835A (zh) * 2019-01-10 2020-07-17 北京师范大学 肝转移癌相关的尿液蛋白标记物的筛选及其用途
CN113777315A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用
CN112147337B (zh) * 2020-08-19 2024-05-28 德赛诊断系统(上海)有限公司 一种富含半胱氨酸蛋白61高敏化学发光检测试剂盒及其制备和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
WO2002026193A2 (en) * 2000-09-29 2002-04-04 Wyeth Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
JP4226471B2 (ja) 2001-09-18 2009-02-18 ファイブローゲン、インコーポレーテッド 結合組織増殖因子の分析方法
JP2003177126A (ja) * 2001-12-13 2003-06-27 Kenichi Katsube Ｃｃｎファミリー蛋白質活性制御剤のスクリーニング方法
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
DK2360475T3 (da) * 2003-03-27 2020-01-06 Childrens Hospital Med Ct Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
CN101120252A (zh) * 2005-02-18 2008-02-06 儿童医疗中心有限公司 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61

Similar Documents

Publication Publication Date Title
JP2008529008A5 (enExample)
JP2008536098A5 (enExample)
Best et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis
US10408839B2 (en) Biomarker panel for diagnosing cancer
Nesterova et al. Autoantibody biomarker opens a new gateway for cancer diagnosis
Sturgeon et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers
Luo et al. Electrochemical sensor for the simultaneous detection of CA72-4 and CA19-9 tumor markers using dual recognition via glycosyl imprinting and lectin-specific binding for accurate diagnosis of gastric cancer
JP5586368B2 (ja) 腫瘍マーカーとしてのｎ１，ｎ１２−ジアセチルスペルミン
Varghese et al. Identification and clinical implementation of biomarkers for Barrett's esophagus
EP3966569A1 (en) Colorectal cancer screening examination and early detection method
JP2015516985A5 (enExample)
JP2014529405A (ja) ヒストン変種含有ヌクレオソーム検出法
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
Bertok et al. Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core
Shimura et al. Serum transthyretin level is associated with prognosis of patients with gastric cancer
JP2018533724A (ja) 肝細胞癌および膵臓がんを診断するためのラミニン２の使用
US20250035633A1 (en) Compositions and methods for detecting cadherin-17 protein
Goggins Markers of pancreatic cancer: working toward early detection
WO2019048588A1 (en) PANEL OF PROTEIN BIOMARKERS AND MIXED AUTO-ANTIBODIES FOR THE DIAGNOSIS OF COLORECTAL CANCER
Zhang et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma
CA3018428C (en) Use of nucleosome-transcription factor complexes for cancer detection
JP2012531612A5 (enExample)
Chen et al. Electrochemical identification of hepatocellular carcinoma based on the assay of human cervical cancer oncoprotein-1 in serum
JP2011209101A (ja) ＣａｐＧをマーカーとする悪性腫瘍の予後予測検査方法
JP2018520366A5 (enExample)